AI Score

Unlock

AI Score

Our AI model analyzes fundamental, technical, and statistical indicators to predict the probability of a bullish trend over the next three months.

We regularly update and refine our models to deliver the most reliable forecasts for you.

Bullish Probability	Sentiment	Score
+80%	Strong Buy	10
+75%	Buy	9
+70%	Buy	8
+60%	Buy	7
+50%	Hold	6
+45%	Hold	5
+40%	Hold	4
+35%	Sell	3
+30%	Sell	2
+20%	Strong Sell	1

Insmed (INSM)

AI Score

Unlock

AI Score

Bullish Probability	Sentiment	Score
+80%	Strong Buy	10
+75%	Buy	9
+70%	Buy	8
+60%	Buy	7
+50%	Hold	6
+45%	Hold	5
+40%	Hold	4
+35%	Sell	3
+30%	Sell	2
+20%	Strong Sell	1

81.24

1.93 (2.43%)

At close: Feb 18, 2025, 3:59 PM

81.77

0.65%

After-hours: Feb 18, 2025, 06:23 PM EST

undefined% (undefined)

Bid	79
Market Cap	14.53B
Revenue (ttm)	-
Net Income (ttm)	-
EPS (ttm)	-5.55
PE Ratio (ttm)	-14.64
Forward PE	n/a
Analyst	Strong Buy

Ask	81.77
Volume	2,160,348
Avg. Volume (20D)	1,795,716
Open	79.83
Previous Close	79.31
Day's Range	78.75 - 82.04
52-Week Range	21.92 - 82.04
Beta	undefined

About INSM

Insmed Incorporated, a biopharmaceutical company, develops and commercializes therapies for patients with serious and rare diseases. The company offers ARIKAYCE for the treatment of Mycobacterium avium complex lung disease as part of a combination antibacterial drug regimen for adult patients. It is also developing Brensocatib, an oral reversible inhibitor of dipeptidyl peptidase 1 for the treatment of patients with bronchiectasis and other neutr...

[Show more]

Industry Biotechnology

Sector Healthcare

IPO Date Jun 1, 2000

Employees 912

Stock Exchange NASDAQ

Ticker Symbol INSM

Website https://www.insmed.com

Full Company Profile

Analyst Forecast

According to 15 analyst ratings, the average rating for INSM stock is "Strong Buy." The 12-month stock price forecast is $90, which is an increase of 10.78% from the latest price.

Buy 93.33%

Hold 0.00%

Sell 0.00%

Stock Forecasts

Next Earnings Release

Insmed is scheduled to release its earnings on Feb 20, 2025, before market opens.
Analysts project revenue of ... Unlock content with Pro Subscription

Why Price Moved

6 months ago

+1.16%

Insmed shares are trading lower after the company ... Unlock content with Pro Subscription

7 months ago

Insmed shares are trading higher after B of A Securities maintained a Buy rating on the stock.

News

1 day ago · zacks.com

Will These 5 Biotech Stocks Surpass Q4 Earnings Forecast?

Let's look at five biotech and drug companies, AXSM, HALO, FOLD, BMRN and INSM, slated to release their fourth-quarter 2024 results this week.

1 day ago · zacks.com

Countdown to Insmed (INSM) Q4 Earnings: Wall Street Forecasts for Key Metrics

Looking beyond Wall Street's top -and-bottom-line estimate forecasts for Insmed (INSM), delve into some of its key metrics to gain a deeper insight into the company's potential performance for the qua...

5 days ago · zacks.com

Insmed (INSM) Expected to Beat Earnings Estimates: What to Know Ahead of Q4 Release

Insmed (INSM) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

1 week ago · seekingalpha.com

Insmed: Priority Review For Brensocatib Cements (Limited) Upside Opportunity

Insmed's Arikayce, a treatment for MAC and NTM lung diseases, generated $93.4m in Q3 2023, with full-year revenue guidance of $340m-$360m. Brensocatib, Insmed's lead pipeline candidate for non-CF bron...

1 week ago · zacks.com

Insmed's NDA for Lung Disease Drug Gets FDA's Priority Review

The FDA accepts and grants priority review to INSM's NDA for brensocatib to treat patients with non-cystic fibrosis bronchiectasis. A decision is due on Aug. 12, 2025.

1 month ago · zacks.com

5 Biotech Breakthrough Stocks to Watch in 2025

After a decent first half, the drug and biotech sector saw a major downturn in the second half due to disappointing third-quarter sales and profits, guidance cuts, pipeline setbacks and the appointmen...

3 months ago · seekingalpha.com

Insmed: PAH Treatment Advancement With 2nd Half 2025 Top-Line Data

Insmed Incorporated's ARIKAYCE, approved for MAC lung disease, achieved strong revenue growth in Q3 of 2024 and potential for expanded FDA approval, boosting its market opportunity. Brensocatib's NDA ...